Angiogenesis Inhibitors: An Update - Can Iressa and Thalomid Rejuvenate the Angiogenesis Inhibitor Class?

Introduction: Despite dozens of angiogenesis inhibitors being investigated in clinical trials, they have failed to live up to expectations and the class has suffered a number of high profile failures. However, there are several promising angiogenesis inhibitors in late stage development, in particular, AstraZeneca's Iressa and Celgene's Thalomid. This brief examines the key angiogenesis inhibitors, the problems encountered by the class and what pharmaceutical companies need to do to avoid these pitfalls.

Scope: * Overview of angiogenesis inhibitors * Profiles of key angiogenesis inhibitors that have failed clinical trial and those in late-stage development * Reasons for the past failures of angiogenesis inhibitors * Key recommendations to avoid the pitfalls. Report Highlights: Angiogenesis inhibitors have been beset with problems. To date, only one agent has been approved in just one market.

One of the main reasons for poor performance of the drug class has been poor clinical trial ... more.

I cant really gove you an answer,but what I can give you is a way to a solution, that is you have to find the anglde that you relate to or peaks your interest. A good paper is one that people get drawn into because it reaches them ln some way.As for me WW11 to me, I think of the holocaust and the effect it had on the survivors, their families and those who stood by and did nothing until it was too late.